Efalizumab for psoriasis

References

• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol.46, 1–23 (2002).
   PubMed Web of Science ®Google Scholar
• de Arruda LH, De Moracs AP. The impact of psoriasis on quality of life. Br. J. Dermatol.144(58), 33–36 (2001).
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol.41, 401–407 (1999).
   PubMed Web of Science ®Google Scholar
• Sterry W, Barker J, Boehncke W-H et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol.151(69), 3–17 (2004).
   PubMed Web of Science ®Google Scholar
• Sterry W. Foreword: the value of the biological therapies for psoriasis management. Br. J. Dermatol.151(69), 1 (2004).
   Google Scholar
• Weinberg JM, Saini R, Turtone WD. Biologic therapy for psoriasis – the first wave: infliximab, etanercept, efalizumab, and alefacept. J. Drugs Dermatol.1, 303–310 (2002).
   PubMedGoogle Scholar
• Weinberg JM, Turtone WD. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept. Cutis71, 41–45 (2003).
   PubMed Web of Science ®Google Scholar
• Schleyer V, Landthaler M, Szeimies R-M. Novel pharmacological approaches in the treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol.19, 1–20 (2005).
   PubMed Web of Science ®Google Scholar
• Menter A, Leonardi CL, Sterry W et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J. Am. Acad. Dermatol.54, S182–S188 (2006).
   PubMedGoogle Scholar
• Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med.349, 2004–2013 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate-to-severe plaque psoriasis. JAMA290, 3073–3080 (2003).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized Phase III trial. J. Am. Acad. Dermatol.52, 425–433 (2005).
   PubMed Web of Science ®Google Scholar
• Ortonne J-P, Shear N, Shumack S et al. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva® (CLEAR) trial [NCT00256139]. BMC Dermatol.5, 13 (2005).
   PubMedGoogle Scholar
• Dubertret L, Sterry W, Bos JD et al. Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a Phase III international randomized, placebo-controlled trial. Br. J. Dermatol.55(1), 170–181 (2006).
   Google Scholar
• Cather JC, Cather JC, Menter A. Modulating T-cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin. Biol. Ther.3, 361–370 (2003).
   PubMed Web of Science ®Google Scholar
• Werther WA, Gonzalez TN, O’Conor SJ et al. Humanization of an anti-lympocyte function-associated antigen (LFA-1) monoclonal antibody and reengineering of the human antibody for binding to rhesus LFA-1. J. Immunol.157, 4986–4995 (1996).
   PubMed Web of Science ®Google Scholar
• Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J. Invest. Dermatol.115, 333 (2000).
   PubMed Web of Science ®Google Scholar
• Leonardi CL. Efalizumab: an overview. J. Am. Acad. Dermatol.49, S98–S104 (2003).
   Google Scholar
• Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm.27, 397–420 (1999).
   PubMedGoogle Scholar
• Gottlieb AB, Miller B, Lowe N et al. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate-to-severe plaque psoriasis. J. Cutan. Med. Surg.7(3), 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Jullien D, Prinz JC, Langley RG et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva®): mechanisms of action. Dermatology208, 297–306 (2004).
   PubMed Web of Science ®Google Scholar
• Raptiva®: Summary of product characteristics. Serono Europe Ltd, London, UK (2005).
   Google Scholar
• Gottlieb A, Krueger JG, Bright R et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol.42, 428–435 (2000).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Gottlieb AB, Miller B et al. Efalizumab (anti-CD11a): results of 12 week trial of subcutaneous administration in patients with moderate-to-severe plaque psoriasis. Poster presented at American Academy of Dermatology, Washington DC, USA, March 2–7 (2001).
   Google Scholar
• Papp K, Bissonnette R, Krueger LG et al. The treatment of moderate-to-severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad. Dermatol.45(5), 665–674 (2001).
   PubMed Web of Science ®Google Scholar
• Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate-to-severe plaque psoriasis. Arch. Dermatol.141, 31–38 (2005).
   Google Scholar
• Carey W, Glazer S, Gottlieb AB et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J. Am. Acad. Dermatol.54, 171–181 (2006).
   PubMed Web of Science ®Google Scholar
• Kragballe K. Biologic agents in psoriasis: mechanisms of action and clinical response. Proceedings of a satellite symposium presented at the 4th Spring Symposium of EADV, Lapland, Finland (2006).
   Google Scholar
• Carlin CS, Feldman SR, Krueger JG et al. A 50% reduction in Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J. Am. Acad. Dermatol.50, 859–866 (2004).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Hamilton T, Caro I et al. Long-term continuous efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis: updated results from an ongoing trial. J. Am. Acad. Dermatol.54, S154–S163 (2006).
   PubMedGoogle Scholar
• Raptiva® (efalizumab) package insert. Genentech Inc., CA, USA (2005).
   Google Scholar
• Papp KA, Bressinck R, Fretzin S et al. Safety of efalizumab in adults with chronic moderate-to-severe plaque psoriasis: a Phase IIIb, randomized, controlled trial. Int. J. Dermatol.45, 605–614 (2006).
   Google Scholar
• Rosoph L. Safety of efalizumab, a humanized monoclonal antibody, in patients with moderate-to-severe plaque psoriasis (abstract). J. Eur. Acad. Dermatol. Venereol.17, 371 (2003).
   PubMed Web of Science ®Google Scholar
• Tsankov N. Which biological to choose? Proceedings of Serono Satellite Symposium presented at the 3rd Spring Symposium of EADV, Sofia, Bulgaria (2005).
   Google Scholar
• Langley RGB, Carey WP, Rafal ES et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin. Ther.27, 1317–1328 (2005).
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths C. Safety and adverse events. In: Pocket Pharma: Efalizumab and Psoriasis. Science Press Ltd, London, UK, 54–57 (2004).
   Google Scholar
• Mrowietz U. Advances in systemic therapy for psoriasis. Clin. Exp. Dermatol.26, 362–367 (2001).
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br. J. Dermatol.153(3), 486–497 (2005).
   PubMed Web of Science ®Google Scholar